Last €89.16 EUR
Change Today -0.118 / -0.13%
Volume 0.0
As of 2:20 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

bio-rad laboratories-a (BUWA) Snapshot

Open
€89.05
Previous Close
€89.28
Day High
€89.16
Day Low
€89.05
52 Week High
02/21/14 - €96.80
52 Week Low
06/13/13 - €81.89
Market Cap
2.6B
Average Volume 10 Days
0.1
EPS TTM
--
Shares Outstanding
23.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIO-RAD LABORATORIES-A (BUWA)

Related News

No related news articles were found.

bio-rad laboratories-a (BUWA) Related Businessweek News

No Related Businessweek News Found

bio-rad laboratories-a (BUWA) Details

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force and a service network worldwide. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

7,750 Employees
Last Reported Date: 03/18/14
Founded in 1952

bio-rad laboratories-a (BUWA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $810.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $423.3K
Executive Vice President and President of The...
Total Annual Compensation: $577.0K
Executive Vice President and President of The...
Total Annual Compensation: $498.4K
Executive Vice President of International Sal...
Total Annual Compensation: $406.7K
Compensation as of Fiscal Year 2013.

bio-rad laboratories-a (BUWA) Key Developments

Bio-Rad Laboratories, Inc. Launches Precision Blue Real-Time PCR Dye

Bio-Rad Laboratories, Inc. has launched its Precision Blue real-time PCR dye. The blue dye improves the visibility of qPCR reaction mixtures, enabling loading of small volume reactions with greater speed, accuracy, and precision. Applications such as single nucleotide polymorphism genotyping and high-throughput gene expression analysis using 384-well plates will particularly benefit from use of this dye. Precision Blue dye is compatible with Bio-Rad's universal qPCR supermixes (iTaq universal and SsoAdvanced universal super mixes) and does not interfere with SYBR Green- or probe-based detection. The dye can be used with all Bio-Rad CFX real-time PCR systems and all other vendors' real-time PCR systems. For convenience, Precision Blue can be added directly to the supermix or used as a component of a reaction master mix. The dye is concentrated 200x, and delivers 500 x 20 µl reactions.

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 22, 2014

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 22, 2014., at 16:00 Pacific Daylight. Location: 1000 Alfred Nobel Drive. Agenda: To elect directors; to ratify the selection of KPMG LLP as the company’s independent auditors for the fiscal year ending December 31, 2014; to approve an amendment to the company’s 2007 incentive award plan to increase the number of shares authorized for sale there under by 600,000 and amend the performance criteria included there under; to consider advisory (non-binding) vote on executive compensation; and to consider such other matters as may properly come before the meeting and at any adjournments or postponements thereof.

Bio-Rad Laboratories, Inc. Amends and Restates Company's By-Laws

On March 25, 2014, the Board of Directors of Bio-Rad Laboratories, Inc. amended and restated the Company's By-laws dated February 19, 1980. The changes effected by the amendment and restatement of the Company's By-laws include, without limitation, the following: SECTION 2. Registered Office: amended the Company's principle place of business from Richmond, California to Hercules, California; SECTION 5. Annual Meetings: amended the date of the Company's annual meeting of stockholders from the month of April to such date and time as specified by the Board and clarified that any other business to be transacted at the annual meeting of stockholders must be properly brought before the meeting in accordance with the By-laws, that notices of a meeting may be given by electronic transmission and that the Board may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled by the Board; SECTION 6. Special Meetings: amended to specify that special meetings shall be called by the Secretary at the request of not less than a majority of the voting power of the stockholders, that the notice for such special meetings shall state the purposes or purposes for which the meeting is called and to delete a provision that allowed business to be transacted at such special meetings which was not stated in the notice by the unanimous written consent of all stockholders represented at the meeting; SECTION 7. Stockholder List: amended to provide that the list of stockholders entitled to vote at meetings shall be kept at the principle place of the Company's business instead of at a place within the city where the meeting is held, as specified in the notice, of if no notice is specified, then at the place where the meeting is held; SECTION 8. Adjourned Meetings and Notice Thereof: amended to allow any officer entitled to preside at or to act as secretary at any stockholders' meeting to adjourn such meetings and to provide that at the adjourned meeting, the Company may transact any business which might have been transacted at the original meeting; SECTION 9. Voting: amended to create new subsections (a) through (d); SECTION 10. Quorum: amended to add of the outstanding shares of stock of the Company entitled to vote at the meeting. at the end of the first sentence; SECTION 11. Consent of Absentees: amended to provide that written waiver of notice of a meeting of stockholders is not required and that if present at a meeting, a stockholder is deemed to have waived notice unless the stockholder attends the meeting only to object to the transaction of business because the meeting is not lawfully called or convened; SECTION 12. Action Without Meeting: amended to clarify that for actions without a meeting of the stockholders: the executed resolutions have to be delivered to the Company, and notice of written action taken shall only be given to those stockholders who would have been entitled to vote on the matter at a meeting; SECTION 13. Proxies: amended the first sentence to state: Every person entitled to vote at any meeting of stockholders or execute consents to corporate action in writing without a meeting shall have the right to do so either in person or by one or more agents authorized by a written proxy executed by such person or his duly authorized agent and filed with the Secretary of the corporation. SECTION 14. Organization and Conduct of Meetings: added this new section, which addresses the conduct at stockholders' meetings, including that the Chairman of the Board shall act as the chairperson, the Board may designate any other director or officer of the Company to act as chairperson in the absence of the Chairman, the Board may adopt rules and regulations for the conduct at meetings, and except to the extent inconsistent with such rules and regulations, the chairperson shall have the right and authority to convene, recess or adjourn the meeting, to prescribe such rules, regulations and procedures and to do all acts the chairperson deems appropriate for the proper conduct of the meeting, such rules, regulations or procedures, include, without limitation, the agenda, polls, order and safety, limitations on attendance or participation, restrictions on entry and limitations on time allotted to questions or comments, except to the extent determined by the Board or chairperson, meetings shall not be required to be held in accordance with parliamentary procedure.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BUWA:GR €89.16 EUR -0.118

BUWA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $36.27 USD -0.13
BioMerieux €78.60 EUR +0.34
PerkinElmer Inc $44.54 USD +0.20
QIAGEN NV €15.30 EUR +0.12
Siemens Ltd 746.90 INR -10.60
View Industry Companies
 

Industry Analysis

BUWA

Industry Average

Valuation BUWA Industry Range
Price/Earnings 46.1x
Price/Sales 1.7x
Price/Book 1.6x
Price/Cash Flow 37.8x
TEV/Sales 0.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-RAD LABORATORIES-A, please visit www.bio-rad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.